# Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

> **NCT00183989** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 30 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Fludarabine, Mitoxantrone and Rituximab

## Key facts

- **NCT ID:** NCT00183989
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-08
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Insufficient accrual
- **Last updated:** 2014-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00183989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00183989, "Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00183989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*